Global Clinical Trials Connect 2026: Turning Innovation into Execution

Global Clinical Trials Connect 2026 brought together sponsors, CROs, technology providers and research organisations to discuss the future of clinical development. While AI, advanced analytics and digital technologies dominated many conversations, one message stood out above all others: the industry is becoming less interested in innovation itself and more interested in measurable outcomes.

For several years, discussions around AI have centred on potential. At this year's conference, the conversation felt noticeably different. Sponsors are no longer asking whether AI can support clinical trials; they're asking where it can create genuine value.

Across study planning, site selection, recruitment forecasting and operational oversight, there is growing recognition that technology should help teams make better decisions faster. However, there was also a healthy level of realism. The challenge now is identifying where technology can meaningfully reduce timelines, improve study performance and support regulatory expectations without introducing unnecessary complexity.

Clinical trial models continue to evolve, but there is no longer a one-size-fits-all approach to study delivery. Rather than pursuing fully decentralised or fully traditional models, sponsors are increasingly looking for solutions that can be adapted to the needs of individual studies, therapeutic areas and patient populations.

This reflects a broader industry trend. Sponsors want approaches that reduce burden, improve access and maintain oversight, but they also need solutions that are practical, scalable and aligned with study objectives. 

"Perhaps the most important takeaway from the conference was the role of collaboration."

As protocols become more complex and development timelines remain under pressure, successful trial delivery increasingly depends on bringing together specialist expertise from across the clinical research ecosystem. Sponsors, CROs, healthcare providers and technology partners all have a role to play, but the greatest value comes when those capabilities are integrated effectively.

Access to specialist operational expertise, flexible delivery models and scalable infrastructure can often determine whether a study progresses efficiently or encounters costly delays.

While the technologies discussed at Global Clinical Trials Connect 2026 were impressive, the conference reinforced a simple reality: clinical development is still about execution.

The organisations that will gain the greatest advantage over the coming years will not necessarily be those with access to the newest technology. They will be those that can combine innovation, expertise and operational excellence to deliver studies more effectively.

At EMS Healthcare, we see this challenge every day. Sponsors and CROs need partners who can help bridge the gap between strategy and execution, providing flexible solutions that support recruitment, site delivery and study operations without adding unnecessary complexity.

As the industry continues to evolve, the focus should remain on one question: how do we deliver better clinical trials, more efficiently? The conversations at Global Clinical Trials Connect 2026 suggest the industry is beginning to move from discussing that challenge to solving it.

For more information on how EMS Healthcare can support your research delivery, connect with Basia on LinkedIn.